Should I buy or sell ChromaDex stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDXC shares. View CDXC analyst ratings or view top-rated stocks .

What is ChromaDex's stock price target for 2024?

2 analysts have issued 12 month target prices for ChromaDex's stock. Their CDXC share price targets range from $5.00 to $6.60. On average, they expect the company's share price to reach $5.87 in the next year. This suggests a possible upside of 51.6% from the stock's current price. View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts .

How have CDXC shares performed in 2024?

ChromaDex's stock was trading at $1.43 at the start of the year. Since then, CDXC shares have increased by 170.6% and is now trading at $3.87. View the best growth stocks for 2024 here .

Are investors shorting ChromaDex?

ChromaDex saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Based on an average trading volume of 259,700 shares, the days-to-cover ratio is currently 5.1 days. Approximately 3.0% of the company's stock are sold short. View ChromaDex's Short Interest .

When is ChromaDex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CDXC earnings forecast .

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) released its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $21.08 million. ChromaDex had a negative trailing twelve-month return on equity of 17.81% and a negative net margin of 5.91%. During the same period in the previous year, the business earned ($0.08) earnings per share.

What is Robert Fried's approval rating as ChromaDex's CEO?

13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com . Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

What other stocks do shareholders of ChromaDex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE) , Heron Therapeutics (HRTX) , ADMA Biologics (ADMA) , Athersys (ATHX) , Bionano Genomics (BNGO) , Matinas BioPharma (MTNB) , Tilray (TLRY) , Dynavax Technologies (DVAX) , Glu Mobile (GLUU) and Great Panther Mining (GPL) .

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CDXC

ChromaDex (CDXC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CDXC Stock Alerts

$3.84

+0.05 (+1.32%)

(As of 10:16 AM ET)

Compare

Today's Range: $3.72
▼
$3.90
50-Day Range: $1.52
▼
$4.32
52-Week Range: $1.25
▼
$4.65

Volume: 80,922 shs
Average Volume: 250,901 shs
Market Capitalization: $289.19 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.87

Get ChromaDex alerts:

ChromaDex MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 51.6% Upside
$5.87 Price Target
Short Interest: Bearish
2.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.62
Upright™ Environmental Score
News Sentiment: 1.24
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.02) to $0.06 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.86 out of 5 stars

Medical Sector

194th out of 918 stocks

Medicinals & Botanicals Industry

1st out of 8 stocks

3.5

Analyst's Opinion

Consensus Rating
ChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
ChromaDex has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.95% of the float of ChromaDex has been sold short.
Short Interest Ratio / Days to Cover
ChromaDex has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in ChromaDex has recently increased by 12.82%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
ChromaDex does not currently pay a dividend.
Dividend Growth
ChromaDex does not have a long track record of dividend growth.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ChromaDex has received a 58.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Dietary supplements" products. See details.
Environmental Sustainability
The Environmental Impact score for ChromaDex is -1.62.

3.5

News and Social Media Coverage

News Sentiment
ChromaDex has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for ChromaDex this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for CDXC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
6 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ChromaDex insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.57% of the stock of ChromaDex is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.41% of the stock of ChromaDex is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for ChromaDex are expected to grow in the coming year, from ($0.02) to $0.06 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ChromaDex is -55.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ChromaDex is -55.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ChromaDex has a P/B Ratio of 10.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About ChromaDex Stock (NASDAQ:CDXC)

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

CDXC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CDXC Stock News Headlines

April 17, 2024 | msn.com

ChromaDex (CDXC) Price Target Increased by 9.92% to 6.60

April 10, 2024 | americanbankingnews.com

ChromaDex (NASDAQ:CDXC) Price Target Increased to $6.00 by Analysts at Roth Mkm

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | stocknews.com

3 Chemical Stocks Poised for Gains

March 26, 2024 | businesswire.com

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

March 8, 2024 | finance.yahoo.com

ChromaDex Full Year 2023 Earnings: EPS Beats Expectations

March 8, 2024 | uk.sports.yahoo.com

Persona 3 Reload is getting the DLC it needs, but not the one it deserves

March 7, 2024 | finance.yahoo.com

ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 7, 2024 | finance.yahoo.com

ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA

March 6, 2024 | markets.businessinsider.com

What Wall Street expects from ChromaDex's earnings

March 6, 2024 | investorplace.com

CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023

March 6, 2024 | benzinga.com

Earnings Preview For ChromaDex

March 6, 2024 | finance.yahoo.com

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

March 2, 2024 | finance.yahoo.com

Insiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the company

February 21, 2024 | finance.yahoo.com

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

February 21, 2024 | businesswire.com

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

February 6, 2024 | entrepreneur.com

Top 3 Accelerating Chemical Stocks to Consider

February 5, 2024 | finance.yahoo.com

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

January 26, 2024 | finance.yahoo.com

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

January 24, 2024 | seekingalpha.com

ChromaDex: Growth At A Reasonable Price

January 19, 2024 | finance.yahoo.com

ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit

December 20, 2023 | businesswire.com

ChromaDex Supports the US Military with its Industry Leading NAD + Supplement, Tru Niagen

December 20, 2023 | baystreet.ca

ChromaDex Flat on Assistance to Military

December 20, 2023 | finance.yahoo.com

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

November 30, 2023 | finance.yahoo.com

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

November 28, 2023 | finance.yahoo.com

An Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 44% Undervalued

See More Headlines

Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/08/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medicinals & botanicals
Sub-Industry: N/A
Current Symbol: NASDAQ:CDXC
CUSIP: N/A
CIK: 1386570
Web: www.chromadex.com
Phone: (310) 388-6706
Fax: 949-419-0294
Employees: 106
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.87
High Stock Price Target: $6.60
Low Stock Price Target: $5.00
Potential Upside/Downside: +54.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,940,000.00
Net Margins: -5.91%
Pretax Margin: -5.91%
Return on Equity: -17.81%
Return on Assets: -9.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.40
Quick Ratio: 1.70

Sales & Book Value

Annual Sales: $83.57 million
Price / Sales: 3.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.38 per share
Price / Book: 9.97

Miscellaneous

Outstanding Shares: 75,310,000
Free Float: 67,349,000
Market Cap: $285.42 million
Optionable: Optionable
Beta: 1.99

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Frank Louis Jaksch Jr. (Age 56)
Co-Founder & Chairman
Comp: $292.27k
Mr. Robert N. Fried (Age 64)
CEO & Director
Comp: $735.54k
Ms. Brianna Gerber (Age 43)
Chief Financial Officer
Comp: $509.82k
Dr. Andrew Shao Ph.D.
Senior Vice President of Global Regulatory & Scientific Affairs
Heather Van Blarcom
Senior VP of Legal & Corporate Secretary
Alex Worsham
Vice President of Global Marketing & Communications
Mr. David Kroes
Senior Vice President of People Matters
Ms. Chu Yan
Managing Director of Asia Pacific
Mr. Jason Campbell
Senior Vice President of Business Development
Kendall Knysch
Head of Media Relations & Partnerships

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CDXC Stock Analysis - Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDXC shares.
View CDXC analyst ratings or view top-rated stocks.
What is ChromaDex's stock price target for 2024?: 2 analysts have issued 12 month target prices for ChromaDex's stock. Their CDXC share price targets range from $5.00 to $6.60. On average, they expect the company's share price to reach $5.87 in the next year. This suggests a possible upside of 51.6% from the stock's current price.
View analysts price targets for CDXC or view top-rated stocks among Wall Street analysts.
How have CDXC shares performed in 2024?: ChromaDex's stock was trading at $1.43 at the start of the year. Since then, CDXC shares have increased by 170.6% and is now trading at $3.87.
View the best growth stocks for 2024 here.
Are investors shorting ChromaDex?: ChromaDex saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Based on an average trading volume of 259,700 shares, the days-to-cover ratio is currently 5.1 days. Approximately 3.0% of the company's stock are sold short.
View ChromaDex's Short Interest.
When is ChromaDex's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CDXC earnings forecast.

How were ChromaDex's earnings last quarter?: ChromaDex Co. (NASDAQ:CDXC) released its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $21.08 million. ChromaDex had a negative trailing twelve-month return on equity of 17.81% and a negative net margin of 5.91%. During the same period in the previous year, the business earned ($0.08) earnings per share.
What is Robert Fried's approval rating as ChromaDex's CEO?: 13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.
What other stocks do shareholders of ChromaDex own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ChromaDex investors own include Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), ADMA Biologics (ADMA), Athersys (ATHX), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Tilray (TLRY), Dynavax Technologies (DVAX), Glu Mobile (GLUU) and Great Panther Mining (GPL).
How do I buy shares of ChromaDex?: Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDXC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ChromaDex (CDXC) Stock Price, News & Analysis

ChromaDex MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ChromaDex Stock (NASDAQ:CDXC)

CDXC Stock Price History

CDXC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CDXC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™